Prostate cancer research has advanced in understanding risk, detection, and treatment. Age is the strongest risk factor, with incidence rising sharply after 50. Family history and certain inherited mutations, such as in BRCA1 and BRCA2, increase risk, as do Black ethnicity and some lifestyle factors, including obesity and diets high in processed meat and saturated fat.

Screening mainly relies on prostate specific antigen (PSA) blood tests and digital rectal examination. Research shows that PSA screening can detect cancers earlier but may also identify slow growing tumors that would never cause harm, leading to overdiagnosis and overtreatment. There is growing emphasis on refining PSA use, incorporating free to total PSA ratios, PSA velocity, risk calculators, and magnetic resonance imaging to better distinguish aggressive from indolent disease.

Diagnostic imaging, particularly multiparametric MRI, has improved the localization and grading of tumors and now guides targeted biopsies. Molecular and genomic tests are being developed to predict tumor behavior more accurately and help select candidates for active surveillance versus immediate treatment.

Treatment research spans surgery, radiotherapy, hormonal therapy, chemotherapy, and newer targeted approaches. Nerve sparing surgery and advanced radiotherapy techniques aim to control cancer while reducing side effects such as urinary incontinence and erectile dysfunction. Androgen deprivation therapy remains a cornerstone for advanced disease, while next generation hormonal agents and chemotherapy combinations improve survival in metastatic and castration resistant cases. Immunotherapy and PARP inhibitors show benefit in selected patients, particularly those with specific DNA repair gene defects. Overall, research is moving toward more personalized, risk adapted management.